Pfizer names leadership team post-Allergan merger
pharmafile | February 9, 2016 | Appointment | Manufacturing and Production, Sales and Marketing | Allergan, Pfizer
Pfizer has announced the executive leadership team for the combined Pfizer and Allergan business once the $160 billiion merger deal closes as anticipated in mid-2016.
Pfizer’s Global Innovative Pharma (GIP) business and its Vaccines, Oncology and Consumer (VOC) business are to immediately operate separately under the leadership of current group president, VOC, Albert Bourla (pictured).
Upon the closing of the transaction, the Vaccines and Oncology businesses will be combined with the GIP business, with Bourla becoming group president, Global Innovative Pharma, leading all of these businesses.
Also following the close of the transaction, the combined company will create a new operating segment named Global Specialty and Consumer Brands that will include Pfizer’s Consumer Healthcare unit and Allergan’s ophthalmology and aesthetics businesses, as well as Botox Therapeutic and Cosmetic. Bill Meury, currently executive vice president and president Branded Pharma at Allergan, will become group president, Global Specialty and Consumer Brands, Pfizer.
After the close of the proposed transaction, Pfizer will continue to manage the combined company’s commercial operations through two distinct businesses: an Innovative Products business and an Established Products business. The Innovative Products business will be composed of two operating segments: the Global Innovative Pharmaceutical and the Global Specialty and Consumer Brands segment. The Established Products business will continue to be led by John Young, and will consist of the Global Established Pharmaceutical segment, including all legacy Hospira commercial operations.
Pfizer also confirmed the following executives as members of the company’s executive leadership team post-merger, reporting to Brent Saunders:
- Albert Bourla, group president, Global Innovative Pharma
- Tony Maddaluna, executive vice president, President Pfizer Global Supply
- Bill Meury, group president, Global Specialty and Consumer Brands
- Laurie Olson, executive vice president, Strategy, Portfolio and Commercial Operations
- John Young, group president, Global Established Pharma
The following Pfizer executives will continue in their roles, reporting to Pfizer chairman and chief executive, Ian Read:
- Frank D’Amelio – executive vice president, Business Operations and chief financial officer
- Mikael Dolsten – president, Worldwide Research and Development
- Chuck Hill – executive vice president, Worldwide Human Resources
- Rady Johnson – executive vice president, chief compliance and risk officer
- Doug Lankler – executive vice president, General Counsel
- Freda Lewis-Hall – executive vice president, chief medical officer
- Sally Susman – executive vice president, Corporate Affairs
Ian Read, chairman and chief executive of Pfizer, comments: “We are creating an executive team that has deep industry knowledge, a proven track record of success and an unwavering commitment to the patients we serve. I look forward to working with these outstanding leaders to achieve the full potential of this combination and fulfil our mission of becoming the premier biopharmaceutical company in our industry. We are designing the combined company to preserve and enhance our option to potentially separate the innovative and established businesses into separate companies in the future, and continue to expect to make a decision about any potential separation by no later than the end of 2018.”
Joel Levy
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
